Treatment Individualization in Colorectal Cancer

Colorectal cancer has been characterized as a genetically heterogeneous disease, with a large diversity in molecular pathogenesis resulting in differential responses to therapy. However, the currently available validated biomarkers KRAS, BRAF, and microsatellite instability do not sufficiently cover...

Full description

Bibliographic Details
Main Authors:	van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Format:	Online
Language:	English
Published:	Springer US 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653238/

id	pubmed-4653238
recordtype	oai_dc
spelling	pubmed-46532382015-11-27 Treatment Individualization in Colorectal Cancer van Geel, Robin M. J. M. Beijnen, Jos H. Bernards, René Schellens, Jan H.M. Therapeutic Approaches to Metastatic Colorectal Cancers (L Vecchione, Section Editor) Colorectal cancer has been characterized as a genetically heterogeneous disease, with a large diversity in molecular pathogenesis resulting in differential responses to therapy. However, the currently available validated biomarkers KRAS, BRAF, and microsatellite instability do not sufficiently cover this extensive heterogeneity and are therefore not suitable to successfully guide personalized treatment. Recent studies have focused on novel targets and rationally designed combination strategies. Furthermore, a more comprehensive analysis of the underlying biology of the disease revealed distinct phenotypic differences within subgroups of patients harboring the same genetic driver mutation with both prognostic and predictive relevance. Accordingly, patient stratification based on molecular intrinsic subtypes rather than on single gene aberrations holds promise to improve the clinical outcome of patients with colorectal cancer. Springer US 2015-08-26 2015 /pmc/articles/PMC4653238/ /pubmed/26617477 http://dx.doi.org/10.1007/s11888-015-0288-z Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	van Geel, Robin M. J. M. Beijnen, Jos H. Bernards, René Schellens, Jan H.M.
spellingShingle	van Geel, Robin M. J. M. Beijnen, Jos H. Bernards, René Schellens, Jan H.M. Treatment Individualization in Colorectal Cancer
author_facet	van Geel, Robin M. J. M. Beijnen, Jos H. Bernards, René Schellens, Jan H.M.
author_sort	van Geel, Robin M. J. M.
title	Treatment Individualization in Colorectal Cancer
title_short	Treatment Individualization in Colorectal Cancer
title_full	Treatment Individualization in Colorectal Cancer
title_fullStr	Treatment Individualization in Colorectal Cancer
title_full_unstemmed	Treatment Individualization in Colorectal Cancer
title_sort	treatment individualization in colorectal cancer
description	Colorectal cancer has been characterized as a genetically heterogeneous disease, with a large diversity in molecular pathogenesis resulting in differential responses to therapy. However, the currently available validated biomarkers KRAS, BRAF, and microsatellite instability do not sufficiently cover this extensive heterogeneity and are therefore not suitable to successfully guide personalized treatment. Recent studies have focused on novel targets and rationally designed combination strategies. Furthermore, a more comprehensive analysis of the underlying biology of the disease revealed distinct phenotypic differences within subgroups of patients harboring the same genetic driver mutation with both prognostic and predictive relevance. Accordingly, patient stratification based on molecular intrinsic subtypes rather than on single gene aberrations holds promise to improve the clinical outcome of patients with colorectal cancer.
publisher	Springer US
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653238/
_version_	1613503991050665984

Treatment Individualization in Colorectal Cancer

Similar Items